RÉSUMÉ

Valeur pronostique des sous-ensembles de lymphocytes du sang périphérique chez les patients atteints de cancer solide: une étude rétrospective

Introduction. Des sous-ensembles de lymphocytes sont importants dans la régulation de l'immunité et la destruction spécifique des cellules tumorales et semblent être fortement associés au développement de tumeurs solides. Cependant, leur pertinence pronostique chez les patients cancéreux reste incertaine.

Le but de l'étude était de déterminer si un sous-ensemble de lymphocytes dans le sang périphérique pouvait constituer des marqueurs pronostiques pour les patients atteints de cancers solides.

Matériel et méthodes. Une recherche dans la base de données de 2010 à 2020 a été menée pour identifier les publications qui explorent l'association des différents sous-ensembles de lymphocytes avec la survie globale et la survie sans maladie chez les patients atteints de cancer.

Résultats. Vingt-neuf articles portant sur 14 tumeurs malignes différentes ont été inclus: 21 paramètres immunitaires évalués avant la chirurgie et 8 après la chirurgie. Sixteen studies reported lymphopenia associated with poor prognosis, other 3 reported increased lymphocytes associated with better prognosis, while 10 studies reported different data: 6 showed correlations between high lymphocyte count and poor prognosis, one study reported low lymphocyte subsets with better prognosis and three reported no impact on prognosis.

ABSTRACT

Introduction. Lymphocyte subsets are important in regulating immunity and specific killing of tumour cells and appear to be strongly associated with the development of solid tumours. However, their prognostic value in cancer patients remains unclear.

The objective of the study was to determine whether peripheral blood lymphocytes subsets might be prognostic markers for patients with solid cancers.

Material and methods. A databases search was conducted to identify publications from 2010 to 2020 exploring the association of different lymphocyte subsets with overall survival and disease-free survival among cancer patients.

Results. Twenty-nine articles referring to 14 different malignancies were included: 21 evaluated the immune parameters before surgery and 8 after surgery. Sixteen studies reported lymphopenia associated with poor prognosis, other 3 reported increased lymphocytes associated with better prognosis, while 10 studies reported different data: 6 showed correlations between high lymphocyte count and poor prognosis, one study reported low lymphocyte subsets with better prognosis and three reported no impact on prognosis.
Conclusions. Lymphocyte depletion, before and after surgery, tends to be associated with reduced survival rate. Postsurgery, lymphocyte subsets could have higher predictive value compared to their preoperative levels and regulatory T cells (Tregs) may be a better prognostic indicator of survival.

Keywords: cancer, lymphocytes, overall survival, disease-free survival, prognosis.

List of the abbreviations:
DFS = disease-free survival; OS = overall survival; PFS = progression free survival; RFS = relapse-free survival; NSCLC = non-small cell lung cancer; Tregs = regulatory T cells; CD = cluster of differentiation; NK = natural killer; FoxP3 = forkhead box protein P3

Introduction

Cancer progression, as well as surgical therapy, can cause stress reactions in patients, which lead to temporary suppression of immune system. In addition, a weak cellular immune function may exert influence on therapeutic efficacy, local recurrence and distant metastases and, consequently, may change into an undesirable prognosis of tumour progression.

The assessment of immune function in cancer patients is mainly based on immune parameters that include T cells (CD3+) specialized in cellular immunity, B cells (CD19+) involved in humoral immunity, and natural killer (NK) cells (CD16+CD56+), that directly kill the tumour cells and virus-infected cells. According to their immunological functions and cell surface markers, CD3+ T cells are mainly subdivided in CD4+ T cells and CD8+ T cells. CD4+ T cells (identified as CD3+ CD4+ T cells) are commonly divided into conventional T helper cells, that play a pivotal role in regulating the immune responses of other immune cells (cytotoxic T cells, B cells and macrophages, and regulatory T cells), while CD8+ T cells (identified as CD3+ CD8+ T cells) are cytotoxic T cells that kill tumour cells by releasing cytokines, cytotoxic granules or by Fas / FasL interactions. Another major cellular component of immune system, B cells, identified as CD19+ cells, possess distinct functions in both adaptive and innate humoral immune responses. They contribute to antitumour immunity in two ways: they produce antitumour antibodies and present antigens to T cells. NK cells, identified as CD16+CD56+ cells, are major cytotoxic effectors cells of the innate immune system, capable of recognizing and destroying tumour cells without prior antigenic exposure, and are involved in coordinating the adaptive immune response.

Tumours can use several mechanisms to suppress host immunity; one of the mechanisms refers to regulatory T cells (Tregs) that help tumours evade immune surveillance. Tregs are a subpopulation of CD4+ CD25+ T lymphocytes that inhibit antitumour immunity by promoting immune tolerance through direct suppressive functions on T-helper and cytotoxic T cells or by secreting immunosuppressive cytokines such as IL-10 and TGF-β. It is claimed that Tregs express and functionally depend on the transcription factor forkhead box protein P3 (FoxP3).

Although lymphocyte subsets are important in regulating immunity and specific killing of tumour cells and appear to be strongly associated with the development of solid tumours, their prognostic relevance in cancer patients remains unclear. Therefore, the aim of this study was to propose a model that includes the following variables: CD3+, CD4+, CD8+, CD19+, CD16+CD56+, Tregs, the type and severity of the disease and the number of cases and to quantify their effect on overall survival (OS) and disease-free survival (DFS) in different types of cancer. The retrospective review of studies published between 2010-2020 on the prognostic value of peripheral lymphocyte subsets was conducted at diagnosis and/or postoperatively only in patients with solid cancer in different stages of the disease. The study was not extended prior to this period due to the lack of consensus in establishing an essential set of Treg markers.

There are several data that were considered in exploring the impact of peripheral blood lymphocytes...
variation on the prognosis of cancer patients before and after surgery: (1) peripheral blood cells can be easily detected and allow real-time monitoring compared to tumour lymphocytes; (2) immune escape of the tumour occurs not only in local immunity but also in systemic immunity; (3) Tregs in peripheral blood are connected to intratumoural Tregs.

**Material and methods**

An electronic search from 2010 to 2020 of the following databases: PubMed, SpringerLink and ScienceDirect was performed. The search strategy was to use different keywords referring to the relationship between different peripheral blood lymphocyte subset counts (CD3+ T cells, CD19+ B cells, CD16+CD56+ NK cells, CD4+ T helper cells, CD8+ T suppressor cells, CD4+CD25+FoxP3+ Treg cells) and prognosis, in patients with solid cancer. In addition, to find all potentially relevant studies, the search field was extended to the reference lists of selected articles.

**Study selection:** In order to reduce the clinical heterogeneity, the following eligibility criteria were utilized: (1) original studies of human subjects with different solid cancers reporting on the prognostic impact of the peripheral blood lymphocytes on OS, and/or DFS or progression-free survival (PFS); (2) only the studies that used the same method of identifying Tregs were selected in this paper; (3) samples collected at diagnosis and/or undergoing surgery treatment; (4) only full text publication; (5) English-language publication. No limitations were applied to the type and severity of cancers, as well as the sex and race of the patients. The exclusion criteria were the following: (1) unrelated to lymphocyte populations established in the selection criteria; (2) case reports, reviews, letters to editors, conference abstracts and (3) insufficient survival information.

**Data extraction:** The following details were extracted from each study: cancer type, tumour stage, number of patients, immune cell type, prognostic markers used to define immune cell type, prognostic indicator/clinical outcomes, and publication. Survival outcomes annotated included DFS, RFS, PFS and OS.

**Results**

**Studies included and their characteristics**

Twenty-nine studies that met the eligibility criteria were included in this review, 21 studies referring to the evaluation of immune parameters before surgery and 8 after surgery.

Table 1 shows the characteristics of the included studies. The publications are reported to be evenly distributed from 2010 to 2020. Fourteen different solid malignancies (breast, colon, rectum, lung, stomach, kidney, pancreas, liver, esophagus, cervix, nasopharynx, gallbladder, ovary, and bladder) were selected according to the eligibility criteria. The largest number of studies were found for gastrointestinal cancers (colorectal cancer – 6 studies, gastric cancer – 3 studies, esophageal cancer and liver cancer – one study, each one), then for lung cancer (5 studies), breast cancer (4 studies), renal cancer (3 studies) and pancreatic cancer (2 studies). Other types of cancer, such as ovarian, cervical, bladder, gallbladder and nasopharyngeal cancers, are each represented by a single study. The sample size of cancer patients, ranged from 30 (cervical and renal cancer) to 1028 (colorectal cancer). The most common parameter investigated was Tregs (in 8 studies), followed by the absolute lymphocyte count, CD4 and NK (in 6 studies), CD19 and CD4/CD8 (in 5 studies) and CD8 (in one study). Sixteen studies, representing 55.17%, reported lymphopenia associated with poor prognosis. Other 3 studies reported increased lymphocytes, associated with better prognosis, while 10 studies reported different data: 6 of them showed a correlation between high lymphocyte count and poor prognosis; one study reported low lymphocyte subsets with better prognosis and three studies reported no impact on prognosis. The end point was OS in 12 studies, PFS/RFS/DFS in 7 studies and poor prognosis in 9 studies. Three studies showed no impact on survival.

**Peripheral blood lymphocyte subsets in patients with solid cancers, before surgery**

Twenty-one studies investigated the prognostic value of peripheral blood lymphocyte subsets in patients with different types of cancer before surgery. The analysis included various solid malignancies such as: colorectal cancer – 5 studies20-24, breast cancer – 4 studies6-19, lung cancer – 4 studies25-28, kidney cancer – 3 studies31-33, gastric cancer – 2 studies29,30 and esophageal14, nasopharyngeal35 and cervical cancer16 – one study. Ten studies performed on patients with different types of cancer have shown that peripheral blood lymphocytes values are independent predictors of OS. Other 5 studies have found associations between the investigated parameters and DFS/RFS or PFS. In contrast, 3 studies did not find associations between the investigated parameters and the clinical outcome.

**Peripheral blood lymphocyte subsets in patients with solid cancers, after surgery**

Eight studies comprising 7 different solid malignancies (gallbladder, pancreatic, liver, colorectal, bladder, non-small cell lung cancer and ovarian...
### Table 1. Summary of characteristics of the included patients

| Cancer type                        | No of patients | Prognostic marker                  | Prognostic indicator/clinical outcomes                                      | Ref. |
|------------------------------------|----------------|-----------------------------------|---------------------------------------------------------------------------|------|
| **Before surgery**                 |                |                                   |                                                                           |      |
| Clear cell renal carcinoma         | 424            | Low absolute lymphocyte count     | Poor OS                                                                   | [31] |
| Papillary renal cell carcinoma     | 192            | Overall lymphopenia               | Poor OS                                                                   | [32] |
| Esophageal cancer                  | 307            | Overall lymphopenia               | Independent marker of poor prognosis                                      | [34] |
| Metastatic breast cancer           | 195            | Overall lymphopenia               | Independent prognostic factor for PFS and OS                              | [16] |
| Rectal cancer and colon cancer     | 121            | High lymphocyte count             | Independent favorable prognostic factor (rectal cancer stage I and II); no prognostic significance (rectal cancer stage III and IV and colon cancer) | [20] |
| Metastatic breast cancer           | 103            | Low absolute CD4+ cells count     | Poor OS                                                                   | [17] |
| Advanced -NSCLC                    | 86             | Low CD3+, CD4+, CD4+/CD8+ and NK cell count | Poor OS                                                                   | [25] |
| Advanced- NSCLC                    | 172            | High CD4+ cells absolute count    | Favorable prognostic factor of PFS                                        | [26] |
| Metastatic breast cancer           | 75             | High CD4+, CD3+, CD4+/CD8+ ratio, CD56+ and CD19+ | Worse survival (high level of CD4+ and CD3+); not prognostic factor (CD4+/CD8+ ratio, CD56+ and CD19+) | [18] |
| Nasopharyngeal cancer              | 356            | Low CD19+ cells count             | Poor PFS and OS                                                           | [35] |
| Gastric cancer                     | 846            | Elevated CD19+ cells count        | Favorable survival; high DFS                                              | [29] |
| Colon cancer                       | 224            | Low percentage of NK cells CD16+56+ | Independent prognostic indicator of shorter survival times                | [21] |
| Gastric cancer                     | 122            | High NK CD16+56+                 | Poor OS                                                                   | [30] |
| Breast cancer                      | 80             | Elevated CD4+/CD8+ ratio          | Poor OS                                                                   | [19] |
| Early-stage NSCLC                  | 80             | Lower CD4+/CD8+ ratio            | Better prognosis                                                          | [27] |
| Advanced cervical cancer           | 30             | High CD4+/CD8 ratio              | Increased risk of having no response to treatment                         | [36] |
| Renal cancer                       | 30             | High Treg                        | Worse prognosis                                                            | [33] |
| NSCLC                              | 67             | High Treg                        | Worse clinicopathological conditions and disease recurrence                | [28] |
| Colon cancer                       | 47             | High Treg                        | No impact on survival                                                      | [22] |
| Colorectal cancer                  | 94 (left colon, 43; rectum, 51) | Low absolute Treg              | No impact on survival                                                      | [23] |
| Colorectal cancer and gastric cancer | 70 (colon, 37; gastric, 33) | Low Treg                          | No impact on survival                                                      | [24] |
| **After surgery**                  |                |                                   |                                                                           |      |
| Gallbladder cancer                 | 34             | Decreased lymphocyte count        | Independent factor of DFS                                                 | [37] |
| Pancreatic cancer                  | 390            | Lymphopenia                       | Independent prognostic factor for OS                                      | [38] |
| Early hepatic cancer               | 158            | CD3+, CD4+, CD8+, NK+, CD19+     | Factor of prediction for the recurrence and independent factor of prognostic | [39] |
| I to III stage colorectal cancer   | 1028           | Low CD4+ cells percentage         | independent prognostic factor of RFS                                      | [40] |
| Pancreatic cancer                  | 56             | Low absolute CD19+ cells and high CD16+CD56+cells | independent risk factors of PFS                                           | [41] |
| Bladder cancer                     | 48             | Decreased Treg                   | Poor prognosis                                                             | [42] |
| NSCLC                              | 49             | Decreased Treg                   | Poor prognosis                                                             | [43] |
| Ovarian cancer                     | 61             | Decreased Treg percentages       | Poor prognosis                                                             | [44] |
cancer) explored the association between peripheral lymphocyte subsets and the outcome of patients. Five of these studies\textsuperscript{37-41} specified association of peripheral blood lymphocytes values with either OS\textsuperscript{38,39} or DFS\textsuperscript{40}, RFS\textsuperscript{41} or PFS\textsuperscript{41}. Three other studies reported that the investigated parameters are associated with a poor prognosis\textsuperscript{42-44}.

**DISCUSSION**

To the best of our knowledge, this is the first review that comprehensively summarizes the prognostic impact of peripheral blood lymphocytes variation on DFS, PFS or OS in patients with various solid malignancies.

**Breast cancer** in women is the most diagnosed cancer, surpassing lung cancer, and the fifth leading cause of cancer death, according to GLOBOCAN 2020 estimates of cancer incidence and mortality provided by the International Agency for Research on Cancer\textsuperscript{45}. Clinical studies revealed that changes in peripheral blood lymphocyte count are closely related to tumour progression and prognosis. In advanced breast cancer, the patients often have lymphopenia and, implicitly, a significantly worse survival than patients with normal lymphocyte counts. Lymphopenia is a powerful predictor of chemotherapy-induced toxicity, in addition to patient’s characteristics, disease characteristics and biological parameters\textsuperscript{16}. Moreover, lymphopenia is associated with an increased risk of febrile neutropenia, thrombocytopenia requiring platelet transfusion, severe anemia requiring red cell transfusion and predisposes the patients to infection, recurrence or to a second malignancy and early death\textsuperscript{46}. There are studies reporting that only some of lymphocytes’ subsets may be altered in lymphopenic patients. It was found that low levels of absolute CD4+ cell counts in peripheral blood at diagnosis are common in patients with advanced breast cancer and are associated with a poor prognosis\textsuperscript{17}. Other studies showed that, conversely, higher levels of CD4+ in HER2-overexpressing metastatic breast cancer patients were significantly correlated with tumour development and a poor prognosis\textsuperscript{35}. However, the authors state that the results failed to show the statistical significance of CD4+ for OS in the multivariate analysis. This may be due to the small sample size or bias caused by unpredictable factors. According to the same authors\textsuperscript{37,38}, CD8+, CD19+ and CD56+ T cell counts have no significant prognostic value for OS. On the other hand, high CD4+/CD8+ ratio, a parameter useful in monitoring disease progression in cancer patients, has been shown to be significantly correlated with tumour progression and low survival rate\textsuperscript{19}. However, the relative role of each lymphocyte subtype is unclear in metastatic breast cancer.

**Colorectal cancer** is the third cancer in incidence and the second in cancer-related mortality\textsuperscript{46}. Despite standard treatment modalities, approximately 40% of patients with colorectal cancer die, indicating a characteristic model of immunodeficiency\textsuperscript{47}. As in other malignancies, the prognostic value of peripheral subsets has been suggested as a promising field in colorectal cancer. Studies show that the preoperative increased lymphocytes count is an independent favorable prognostic factor for patients with early-stage rectal cancer. In contrast, in patients with advanced rectal cancer, as well as those with colon cancer, the preoperative lymphocytes counts would not have a prognostic significance\textsuperscript{20}. Among lymphocytes, natural killer (NK) cells could serve as biomarkers for monitoring the immune system, their prognostic value being described in colorectal cancers, where decreases in NK cells number are often observed\textsuperscript{21}. Patients with colon cancer who have a significantly lower NK cell counts have shorter survival times than those with higher counts. Other subsets of T lymphocytes involved in the interaction of colorectal tumours and the host immune system and which may affect the immune response against cancer are Tregs lymphocytes. The unambiguous enumeration of Tregs was hampered in the previous years by the inability to directly measure their function and the absence of an exclusive, highly specific marker. The consensus on an essential marker set for Treg enumeration with the currently available markers was established after 2010. Only the studies that used the same method of identifying Tregs, namely CD3+CD4+CD25+FoxP3+, were selected in this paper. In colorectal cancer, a heterogeneous disease, with many variations stemming from its primary tumour location, the prognostic role of Treg is controversial\textsuperscript{22-24}. Increases in Treg amounts were observed in some tumour types and sites, or conversely, decreases compared to healthy controls. Tregs were found to be significantly higher in the peripheral blood of patients with advanced colon cancer compared to healthy controls\textsuperscript{23}. This is contradicted by the results obtained by another study, which has found that the absolute number of Tregs in the peripheral blood of patients with left-sided colon cancer has decreased, especially in advanced stages of disease, compared to healthy controls\textsuperscript{23}. However, the difference between stage I and the other stages did not reach statistical significance, but there was a tendency for a lower Treg counts in stages III and IV than in stage I. This difference was not investigated in a previous study\textsuperscript{24} due to the small number of patients. All these studies showed that Tregs have no impact on survival. Thus, contrary to the findings observed in other
cancers, no significant relation between the number of Treg cells and prognosis was observed in several studies with colorectal cancer patients. Nevertheless, there are not sufficient data to compare the results of studies.

**Lung cancer** remains the leading cause of cancer death, with approximately 1.8 million deaths (18%), according to GLOBOCAN 2020 estimates. The immunophenotypic profile on peripheral blood lymphocytes in patients with NSCLC and healthy controls was evaluated in various studies. Furthermore, comparisons between NSCLC patients, with and without metastasis, were also performed. Four studies and 405 eligible NSCLC patients participated in this analysis, showing that immunosuppression is commonly associated in patients with advanced-stage cancers. Thus, a study reported that low levels of absolute CD4+ cell count in the peripheral blood at diagnosis are common in patients with advanced NSCLC and are associated with a poor prognosis. Consistently, a high level of absolute CD4+ cells count in patients with advanced NSCLC contributed to longer PFS. Prolonged depletion of CD4+ populations appears to lead to prolonged impairment of immune function, limiting the ability of the immune system to eradicate minimal residual neoplastic disease. As well as in colorectal cancer, patients with a significantly lower NK cell count have shorter survival time than those with higher counts. On the other hand, studies showed that low level of CD4+/CD8+ ratio correlates with a better prognosis in the early stages of disease and a poor prognosis in advanced disease. These results are consistent with literature data showing that CD4+/CD8+ ratio decrease can be frequently identified in patients with disseminated disease. The shift in this ratio in cancer patients may be due to a decrease in T-helper and/or an increase in T-suppressor lymphocytes. Therefore, the results of the present study showed that the lymphocyte subsets count in NSCLC with metastasis is significantly lower compared to the lymphocytes in the early-stage NSCLC, supporting the hypothesis that lymphocyte decrease is associated with tumour progression. In addition, since tumour with metastasis is indicative of a poor prognosis, the findings support that lymphopenia is an independent prognostic factor for OS and PFS. Referring to Tregs, it has been observed that an increased number of these lymphocyte subsets accumulate in tumours and the peripheral blood of patients with cancer, and their increased frequency is generally considered to be the marker of a poor prognosis in cancer, presumably due to the Treg-mediated suppression of antitumour immunity. Thus, the significantly increased Tregs are correlated with severe clinicopathological conditions and recurrence.

Changes in peripheral lymphocyte subpopulations have also been observed in *gastric cancer*. Significantly lower CD3+ and CD8+ percentages and significantly elevated levels of CD4+, CD19+, NK cells, as well as a high CD4+/CD8+ ratio were found in the peripheral blood of 846 gastric cancer patients and 96 control donors. However, it was found that only CD19+ positively correlated with survival. Increased CD19+ expression appears to improve the humoral immunity, thereby modifying the immune status and prognosis, and further improving the DFS. In contrast, in a recent study it was reported that CD19+ B cells in patients were not significantly different from those of controls. Also, CD3+, CD4+, CD8+ T cells, and Tregs in patients were not different from those of controls. Only NK cells proportion in patients was significantly higher than that in healthy donors and is associated with a poor prognosis. This result is in contradiction with the above-mentioned data about colorectal cancer and NSCLC. According to the biological function of NK cells, both the direct cytoxicity and immune modulation effect are involved in NK cell mediated antitumour effects in gastric cancers. It can also be speculated that the sample size (122 patients) may have led to different results. Also, the prognostic values of blood cells based on different cut-off values through different methods were not compared. On the other hand, in a relatively small number of cases (33 patients) a significant decrease in the absolute Treg number was observed compared to healthy controls, but with no impact on patient survival.

The clinical significance of peripheral blood parameters is a potential prognostic indicator for *renal cancer*. In this review, we found only 3 research groups that evaluated the prognostic value of peripheral blood lymphocyte subsets in patients with renal carcinoma, at diagnosis. Two articles, one on clear cell renal carcinoma (424 patients) and the second on papillary renal cell carcinoma (192 patients) showed lymphopenia, that has been found to predispose the patients to infections, recurrence or to a second malignancy and is associated with a poor PFS and OS. In another article, Treg was evaluated in the peripheral blood of renal cell carcinoma patients based on the most appropriate phenotype CD4+ CD25+ FoxP3+ T cells. It has been shown, as in NSCLC, that increased Tregs can inhibit antitumour immune responses, leading to tumour development and progression and correlates with a poor prognosis and decreased survival.

For other three cancers (*esophageal, nasopharyngeal or cervical*), taking into account the inclusion criteria, only single studies were found in the literature. Thus, in esophageal squamous cell
in patients following radical surgical resection 41. In treatment increases the risk of having no response to therapy for survival. Similarly, in advanced cervical cancer patients, the higher CD4+/CD8+ ratio before treatment increases the risk of having no response towards treatment 46.

From the published studies, where the assessment of the number of cells was performed only preoperatively, it can be observed that there is no consensus on the extent of changes in different lymphocytes subsets during cancer progression. The use, especially of CD4+ and CD8+, as prognostic markers is unclear, mainly due to the complexity of T helper subsets. Moreover, CD4+ and CD8+ values may be different for various types of cancer. There is also heterogeneity among patients, and among hospitals with respect to technology, which may influence the results. However, it should be noted that most publications show that the absolute values of lymphocyte subsets provide a better indication of the patient’s immune status than the percentage values of each lymphocyte subset.

Surgical resection is the most widely used treatment for solid cancers, especially for localized diseases. This may cause stress reactions in patients, leading to immunity suppression, mainly by changing the different lymphocyte subsets count.

Studies reported that the peripheral lymphopenia, especially after surgical resection, has been shown to be an independent predictive and prognostic factor for DFS in gallbladder cancer 47 and for OS in pancreatic cancer 48. These studies also suggest that peripheral blood lymphocytes count may have an additive value regarding conventional prognostic factors for death-risk stratification and to predict long-term survival. CD3+, CD4+, CD8+, CD19+ and NK+ markers strongly correlated with survival rate in hepatocellular carcinoma before surgery and have a considerable predictive value for malignant characteristics and prognosis. Postoperatively, they are an important predictor of recurrence and an independent prognostic factor 49. Also, postoperative peripheral CD4+ T cells percentage is a predictive biomarker for RFS in colorectal cancer; this parameter may be useful in identifying patients who will benefit from adjuvant chemotherapy 50. High absolute counts for peripheral NK cells and low B cell counts may independently predict the progression and were associated with PFS in pancreatic neuroendocrine tumours in patients following radical surgical resection 51. In healthy individuals, Treg cells play an important role in the maintenance of self-tolerance. We searched the literature to see whether surgical treatment in patients affects Treg level and, implicitly, the survival. From the published data, it was observed that the increase of Treg cells in various cancers, such as bladder cancer, NSCLC or ovarian cancer 52-54 and their decrease after tumour removal at levels almost equal to those of healthy donors correlated with a poor prognosis. It appears that Treg cells have a different influence at different stages of cancer development, with an increase in Treg cell number in patients with metastatic cancer, compared to that found in patients with localized disease. The higher proportion of Treg in patients with advanced cancer than in those in early stage suggests the potential role of Treg as a clinical biomarker to indicate a poor prognosis, which may help to stratify patients and adapt their therapy 52.

Although the peripheral lymphocyte subsets have been shown to be biomarkers of immune status and are related to patient survival in many cancer types, at present, there is a lack of direct evidence for peripheral immune profile in cancer patients. However, clinical practice has shown that the improvement of immune parameters and, implicitly, of immune function, can lead to a favorable prognosis, a better clinical outcome, and a better response to anti-cancer therapy, especially if immunostimulatory treatments are applied. However, from a therapeutic perspective, a simple increase in the absolute lymphocytes count may not be enough to promote clinically significant antitumour responses.

Limitations of the study
This review has some limitations:

- There are differences in patients’ age, sex, stage of the disease, histological type, underlying disease, etc., limiting the direct comparison of immune changes in cancers. In addition, these baseline patient characteristics may all have a significant impact on test results.
- The studies focused on different tumours, which are inherently heterogeneous. Heterogeneity was also manifested not only between patients, but also between hospitals in terms of technology (method, antibodies, analysis equipment), which could have affected the results.
- It should be considered that the peripheral blood lymphocytes counts may be affected by concomitant conditions, such as infections, inflammation and medications.
- Due to the substantial heterogeneity in our study, we were unable to perform group statistical analysis based on cancer type, histological grade or clinical stage.
- Only article published in English were included, which could lead to publication bias.
We did not contact the authors of the included studies to acquire detailed information of patients.

**Conclusions**

Several studies investigated the extent to which changes in peripheral lymphocyte subsets correlate with tumor progression and prognosis, in various types of cancer. Although peripheral lymphopenia, identified as pre-existing or induced by surgical therapy in patients with solid tumors, affects survival, there is no consensus on the extent of changes in different lymphocytes subsets during cancer progression or in relationship with response to tumour-specific therapy or survival.

Most of publications refer to the fact that the absolute lymphocytes subset values provide a better indication of the patient’s immune status than the percentages of each lymphocyte subsets and should be considered when evaluating the prognosis. However, it can be suggested that a panel of peripheral blood immune markers can complete the patient’s immune status and add value to the patient’s prognosis, thus being able to direct/redirect the choice of therapy.

**Author Contributions:**

M.E.P. conceived the original draft preparation. M.E.P., A.B., and L.M.B. were responsible for conception and design of the review. A.M.C., and M.S. were responsible for the data acquisition. M.E.P., A.B., A.M.C., M.S., and L.M.B. were responsible for the collection and assembly of the articles/public data, and their inclusion and interpretation in this review. M.E.P., A.B., A.M.C., M.S., and L.M.B. contributed equally to the present work. All authors contributed to the critical revision of the manuscript for valuable intellectual content. All authors have read and agreed with the final version of the manuscript.

**Compliance with Ethics Requirements:**

“The authors declare no conflict of interest regarding this article”

“No funding for this study”

**Acknowledgements:**

None

**References**

1. Yoshimoto Y, Kono K, Suzuki Y. Anti-tumor immune responses induced by radiotherapy: A review. Fukushima Journal of Medical Science 2015;61(1):13–22.

2. Lv Y, Song M, Tian X, Yu X, Liang N, Zhang J. Impact of radiotherapy on circulating lymphocyte subsets in patients with esophageal cancer. Medicine (Baltimore). 2020;99(36):e20993.

3. An N, Wang H, Jia W, et al. The prognostic role of circulating CD8+ T cell proliferation in patients with untreated extensive stage small cell lung cancer. Journal of Translational Medicine 2019;17:402.

4. Hong M, Jiang Z, Zhou YF. Effects of thermotherapy on Th1/Th2 cells in esophageal cancer patients treated with radiotherapy. Asian Pacific Journal of Cancer Prevention 2014;15(5):2359–2362.

5. Ortegel JW, Staren ED, Faber LP, Warren WH, Braun DP. Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung Cancer 2002; 36(1):17-25.

6. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+T cells: differentiation and functions. Clinical & Developmental Immunology 2012; 925135. doi:10.1155/2012/925135.

7. Tian C, Lu S, Fan Q, et al. Prognostic significance of tumor-infiltrating CD8+ or CD3+ T lymphocytes and interleukin-2 expression in radically resected non-small cell lung cancer. Chinese Medical Journal 2015;128(10):105–110.

8. Qiu J, Zhou F, Li X, et al. Changes and clinical significance of detailed peripheral lymphocyte subsets in evaluating the immunity for cancer patients. Cancer Management and Research 2020;12:209–219.

9. Lumnickby K, Candéias SM, Gapil US, Frey B, Editorial: Radiation and the immune system: current knowledge and future perspectives. Frontiers in Immunology 2018; 8: 1933.

10. Bryceson YT, Chiang SC, Darmanin S, et al. Molecular mechanisms of natural killer cell activation. Journal of Innate Immunology 2011;3(3):216–226.

11. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes & Development 2018; 32(19-20):1267–1284.

12. Lim KP, Chun NAL, Ismail SM, et al. CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients. 2014; PLoS ONE 9(8): e103975.

13. Rodriguez-Perea AL, Arcia ED, Rueda CM, Velilaa PA. Phenotypical characterization of regulatory T cells in humans and rodents. Clinical and Experimental Immunology 2016;185(3):281–291.

14. Teng MW, Galon J, Fridman WH, Smyth MJ. From mice to humans: developments in cancer immunediting. The Journal of Clinical Investigation 2015;125:3338–3346.

15. Pereira LMS, Gomes STM, Ishak R, Vallinoto ACR. Regulatory T cell and Forkhead Box Protein 3 as modulators of immune homeostasis. Frontiers in Immunology 2017;8:605.

16. De Giorgi U, Mego M, Scarpi E, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clinical Breast Cancer 2012;12(4):264–269.

17. Tredan O, Manuel M, Clapissone G, et al. Patients with metastatic breast cancer leading to CD4+ T cell lymphopenia have poor outcome. European Journal of Cancer 2013;49(7):1673–1682.

18. Yang J, Xu J, E Y, Sun T. Predictive and prognostic value of circulating blood lymphocyte subsets in metastatic breast cancer. Cancer Medicine 2019; 8(2):492–500.

19. Yang X, Ren H, Sun Y, et al. Prognostic significance of CD4+/CD8 ratio in patients with breast cancer. International Journal of Clinical and Experimental Pathology 2017;10(4):4787-4793.

20. Zhang YY, Li WQ, Li ZF, et al. Higher levels of pre-operative peripheral lymphocyte count is a favorable prognostic factor for patients with stage I and II rectal cancer. Frontiers in Oncology 2019;9:960.
21. Tang Y, Xie M, Li K, et al. Prognostic value of peripheral blood natural killer cells in colorectal cancer. BMC Gastroenterology 2020;20:31.

22. Sellitto A, Galizia G, De Fanis U, et al. Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery. Journal of Clinical Immunology 2011; 31(6):1095-1104.

23. Dylag-Trojanowska K, Rogala J, Pach R, et al. T-Regulatory CD4+CD25+ Foxp3+ lymphocytes in the peripheral blood of left-sided colorectal cancer patients. Medicina (Kaunas). 2019;56(6):307.

24. Szczepanik AM, Siedlar M, Sierzega M, et al. T-regulatory lymphocytes in peripheral blood of gastric and colorectal cancer patients. World Journal of Gastroenterology 2011;17(3):343-348.

25. Wang WJ, Tao Z, Gu W, Sun LH. Variation of blood T lymphocyte subgroups in patients with non-small cell lung cancer. Asian Pacific Journal of Cancer Prevention 2013;14(8):4671-4673.

26. Xia Y, Li W, Li Y, et al. The clinical value of changes of peripheral CD4+CD25+Foxp3+ lymphocytes in the peripheral blood of left-sided colorectal cancer patients. Medicina (Kaunas). 2019;56(6):307.

27. Rutkowski J, Cyman M, Slebioda T, et al. Evaluation of regulatory CD4+CD25+Foxp3+ lymphocytes in the peripheral blood of left-sided colorectal cancer patients. Medicina (Kaunas). 2019;56(6):307.

28. Hasegawa T, Suzuki H, Yamaura T, et al. Prognostic value of peripheral blood lymphocyte subsets in patients with solid cancers… – PANAIT et al

29. Yu QM, Yu CD, Ling ZQ. Elevated circulating CD19+ lymphocytes predict survival advantage in patients with gastric cancer. Asian Pacific Journal of Cancer Prevention 2012; 13(5): 2219-2224.

30. Chen YY, Feng Y, Mao QS, et al. Diagnostic and prognostic value of the peripheral natural killer cell level in gastric cancer. Experimental and Therapeutic Medicine 2020; 19(4):3816-3822.

31. Saroha S, Utzo RG, Plimack ER, Ruth K, Al-Saleem. Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. The Journal of Urology 2013;189:454-461.

32. Chen YY, Feng Y, Mao QS, et al. Diagnostic and prognostic value of the peripheral natural killer cell level in gastric cancer. Experimental and Therapeutic Medicine 2020; 19(4):3816-3822.

33. Liotta F, Gacci M, Frosali F, et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. British Journal of Urology International 2011;107:1500-1506.

34. Feng JF, Liu JS, Huang Y. Lymphopenia predicts poor prognosis in patients with esophageal squamous cell carcinoma. Medicine (Baltimore) 2014; 93(27):e257.

35. Xu T, Huang Z, Su B, et al. Prognostic significance of circulating CD19+ B lymphocytes in EBV-associated nasopharyngeal carcinoma. Medical Oncology 2014; 31: 198.

36. Sanif R, Nurwany R. Prognostic significance of CD4/CD8 ratio in patients with advanced cervical cancer. Journal of Physics: Conference Series 2012;1246. 2019;012053.

37. Iwase R, Shiba H, Haruki K, et al. Post-operative lymphocyte count may predict the outcome of radical resection for gallbladder carcinoma. Anticancer Research 2013;33 (8): 3439-3444.

38. D’Engremont C, Vernerney D, Pointet AL, et al. Additive value of pre-operative and one-month post-operative lymphocyte count for death risk stratification in patients with resectable pancreatic cancer: a multicentric study. BMC Cancer 2016;16 (1):823.

39. Che YQ, Feng L, Rong WQ, et al. Correlation analysis of peripheral blood T cell subgroups, immunoglobulin and prognosis of early hepatocellular carcinoma after hepatectomy. International Journal of Clinical and Experimental Medicine 2014;7(11):4282-4290.

40. Li Z, Li S, Liang Y, et al. Predictive value of postoperative peripheral CD4+T cells percentage in stage I–III colorectal cancer: a retrospective multicenter cohort study of 1028 subjects. Cancer Management and Research 2020;12:5505-5513.

41. Gong Y, Fan Z, Luo G, et al. Absolute counts of peripheral lymphocyte subsets correlate with the progression-free survival and metastatic status of pancreatic neuroendocrine tumour patients. Cancer Management and Research 2020;12:6727-6737.

42. Jóźwicki W, Brożyna AA, Siciak J, Slominski AT. Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal. Oncotarget 2016;7(10):11450–11462.

43. Chen C, Chen D, Zhang Y, et al. Changes of CD4+CD25+Foxp3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery. International Immunopharmacology 2014;18(2):255-261. https://doi.org/10.1016/j.intimp.2013.12.004.

44. Wu M, Chen X, Lou J, et al. Changes in regulatory T cells in patients with ovarian cancer undergoing surgery: Preliminary results. International Immunopharmacology 2017;47:244-250.

45. International Agency for Research on Cancer. Global Cancer Observatory. http://gco.iarc.fr (Accessed on December 12, 2020).

46. Ménétrier-Caux C, Ray-Coquard I, Blay JY, Caux C. Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines?. Journal for ImmunoTherapy of Cancer 2019;7(1):85.

47. Pernot S, Termé M, Voron T, et al. Colorectal cancer and immunity: what we know and perspectives. World Journal of Gastroenterology 2014; 20(14): 3738-3750.